IRIX news

Latest 1 stories · newest May 19, 2026

IRIX

IRIDEX Q1 2026 revenue declined 1% to $11.8M; net loss narrowed to $0.5M

Iridex reported flat revenue with Cyclo G6 glaucoma product growing 14% offset by retina product decline, while net loss improved significantly year-over-year. The company affirmed 2026 guidance and expects cash flow positive results this fiscal year as cost reduction initiatives take effect.

Earnings May 19, 2026 sentiment +0.35 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same IRIX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/IRIX/newsSTART FREE